IONS (Ionis Pharmaceuticals) Interest Income: $0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IONS Ionis Pharmaceuticals Inc IONS
70 GF Score
Price $59.00
GF Value $48.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Interest Income?

Ionis Pharmaceuticals IONS +0.63% 70 Interest Income is $0.0 Mil as of Jun. 2026. GuruFocus rates IONS with a GF Score™ of 70/100 and a GF Value™ of $48.10 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Ionis Pharmaceuticals's interest income for the three months ended in Jun. 2026 was $0.0 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $0.0 Mil.

Ionis Pharmaceuticals Interest Income Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Interest Income Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IONS
70GF Score
Ionis Pharmaceuticals Inc IONS
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $0.0 Mil mean?
Ionis Pharmaceuticals (IONS) has a Interest Income of $0.0 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Interest Income too high?
Ionis Pharmaceuticals' current Interest Income is $0.0 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Interest Income compare to KYMR and PRAX?
Ionis Pharmaceuticals' Interest Income of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Interest Income is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (IONS) is currently considered Modestly Overvalued. The stock's GF Value™ is $48.10, compared to a current price of $59.00 — trading 22.7% above its estimated fair value. The current Interest Income is $0.0 Mil. Ionis Pharmaceuticals' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Ionis Pharmaceuticals (IONS), the current Interest Income is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $59.00 is trading 22.7% above its estimated GF Value™ of $48.10. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for IONS:

  • Interest Income: $0.0 Mil
  • GF Value™: $48.10 vs. price of $59.00 (22.7% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
70GF Score

Get the complete analysis for IONS

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.00
Price
$48.10
GF Value